1.76
price up icon5.39%   0.09
after-market After Hours: 1.74 -0.02 -1.14%
loading
Werewolf Therapeutics Inc stock is traded at $1.76, with a volume of 770.60K. It is up +5.39% in the last 24 hours and up +23.08% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.67
Open:
$1.645
24h Volume:
770.60K
Relative Volume:
1.22
Market Cap:
$80.48M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.6923
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-6.38%
1M Performance:
+23.08%
6M Performance:
+105.18%
1Y Performance:
-12.44%
1-Day Range:
Value
$1.645
$1.78
1-Week Range:
Value
$1.56
$1.9371
52-Week Range:
Value
$0.595
$4.18

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name
Name
Werewolf Therapeutics Inc
Name
Phone
617-952-0555
Name
Address
200 TALCOTT AVENUE, WATERTOWN
Name
Employee
46
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HOWL
Werewolf Therapeutics Inc
1.76 76.37M 19.94M -37.37M -33.38M -1.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.90 105.69B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
470.27 61.52B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
576.42 60.69B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
815.61 50.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
316.15 35.25B 4.56B -176.77M 225.30M -1.7177

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Initiated JMP Securities Mkt Outperform
Aug-24-23 Initiated Wedbush Outperform
Jun-06-23 Resumed Jefferies Buy
Sep-10-21 Initiated BofA Securities Buy
May-25-21 Initiated Evercore ISI Outperform
May-25-21 Initiated H.C. Wainwright Buy
May-25-21 Initiated Jefferies Buy
May-25-21 Initiated SVB Leerink Outperform
View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

pulisher
12:23 PM

Using data tools to time your Werewolf Therapeutics Inc. exit2025 Big Picture & High Conviction Buy Zone Picks - newser.com

12:23 PM
pulisher
12:16 PM

Identifying reversal signals in Werewolf Therapeutics Inc.2025 Risk Factors & Intraday High Probability Alerts - newser.com

12:16 PM
pulisher
11:08 AM

Werewolf Therapeutics Inc. stock trendline breakdown2025 Volatility Report & Free Expert Verified Stock Movement Alerts - newser.com

11:08 AM
pulisher
05:35 AM

Will Werewolf Therapeutics Inc. stock outperform growth indexesEntry Point & Weekly Breakout Opportunity Watchlist - newser.com

05:35 AM
pulisher
Oct 14, 2025

Intraday pattern recognizer results for Werewolf Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Predicting Werewolf Therapeutics Inc. trend using moving averagesSwing Trade & Reliable Volume Spike Alerts - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Analyzing recovery setups for Werewolf Therapeutics Inc. investorsJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria

Oct 08, 2025
pulisher
Oct 08, 2025

Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com

Oct 08, 2025
pulisher
Oct 08, 2025

Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire

Oct 08, 2025
pulisher
Oct 08, 2025

Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan

Oct 08, 2025
pulisher
Oct 06, 2025

Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks

Oct 06, 2025
pulisher
Oct 06, 2025

Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛

Oct 04, 2025
pulisher
Oct 03, 2025

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative

Oct 03, 2025
pulisher
Oct 03, 2025

3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan

Oct 03, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 05:19:05 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 01:50:53 - newser.com

Sep 30, 2025

Werewolf Therapeutics Inc Stock (HOWL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Werewolf Therapeutics Inc Stock (HOWL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RA CAPITAL MANAGEMENT, L.P.
Director
May 14 '25
Buy
0.98
162,539
159,288
6,237,482
RA CAPITAL MANAGEMENT, L.P.
Director
May 13 '25
Buy
0.98
52,974
51,915
6,074,943
MPM BioVentures 2014, L.P.
10% Owner
Mar 27 '25
Sale
1.05
1,963
2,061
3,208,793
EVNIN LUKE
Director
Mar 27 '25
Sale
1.05
2,425
2,546
4,309,860
GADICKE ANSBERT
10% Owner
Mar 27 '25
Sale
1.05
4,386
4,605
6,718,670
$22.64
price up icon 4.09%
$88.15
price up icon 2.55%
$32.72
price down icon 0.09%
$104.34
price up icon 1.69%
$163.54
price up icon 1.34%
biotechnology ONC
$316.15
price down icon 1.49%
Cap:     |  Volume (24h):